Last reviewed · How we verify
OPC-34712 + ADT
OPC-34712 is a selective serotonin 5-HT7 receptor antagonist combined with androgen deprivation therapy (ADT) to treat prostate cancer.
OPC-34712 is a selective serotonin 5-HT7 receptor antagonist combined with androgen deprivation therapy (ADT) to treat prostate cancer. Used for Prostate cancer (in combination with androgen deprivation therapy).
At a glance
| Generic name | OPC-34712 + ADT |
|---|---|
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Drug class | 5-HT7 receptor antagonist |
| Target | 5-HT7 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
OPC-34712 blocks the 5-HT7 receptor, which may enhance the efficacy of standard androgen deprivation therapy in prostate cancer by modulating serotonergic pathways involved in tumor progression. The combination approach aims to improve outcomes in hormone-sensitive or castration-resistant prostate cancer by targeting complementary mechanisms.
Approved indications
- Prostate cancer (in combination with androgen deprivation therapy)
Common side effects
- Fatigue
- Hot flashes
- Sexual dysfunction
- Nausea
Key clinical trials
- Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder (PHASE4)
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder (PHASE3)
- Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress (PHASE3)
- A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial (PHASE3)
- Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder (PHASE2)
- Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) (PHASE3)
- Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial) (PHASE3)
- Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |